Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Jezperklauzen/iStock via Getty Images
Receipt of ‘orphan drug’ designation for company’s CAR-T cancer drug in the U.S. will bring financial incentives, but also underscores drug’s limited market potential.
Gracell Biotechnologies Inc. (NASDAQ:GRCL), a…
